Online inquiry

IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12073MR)

This product GTTS-WQ12073MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12073MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12457MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ1613MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ4984MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ11395MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ6660MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ12312MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ5367MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ8575MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Hu5F9-G4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW